Comparison of relapse rates in Behçet's disease with venous involvement on different doses of azathioprine therapy, a retrospective observational study.
Adult
Azathioprine
/ administration & dosage
Behcet Syndrome
/ diagnosis
Female
Humans
Immunosuppressive Agents
/ administration & dosage
Male
Middle Aged
Progression-Free Survival
Recurrence
Remission Induction
Retrospective Studies
Thrombophlebitis
/ diagnosis
Time Factors
Turkey
Venous Thrombosis
/ diagnosis
Young Adult
Behçet's disease
azathioprine
venous involvement
Journal
International journal of rheumatic diseases
ISSN: 1756-185X
Titre abrégé: Int J Rheum Dis
Pays: England
ID NLM: 101474930
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
revised:
27
12
2020
received:
11
10
2020
accepted:
12
01
2021
pubmed:
28
2
2021
medline:
11
11
2021
entrez:
27
2
2021
Statut:
ppublish
Résumé
The aim of this study was to investigate relapse rates in azathioprine (AZA) maintenance therapy at different doses in Behçet's disease (BD) with venous involvement. Clinical records of patients who met the diagnostic criteria of International Study Group (ISG) for BD, were diagnosed with venous involvement of BD for at least 6 months and sustained clinical remission with AZA for at least 3 months were analyzed retrospectively. The analysis cohort was divided into 2 groups based on AZA dose (Group A: ≥ 2 mg/kg/d and Group B: <2 mg/kg/d). Relapse was defined as requiring another antirheumatic/immunosuppressive drug or more than dose of 10 mg/d of prednisolone. Of 78 patients who were included into the study, there was no significant difference between the 2 groups in terms of age, gender and clinical characteristics. Mean relapse-free survival time was found to be higher in group A compared to group B (111.6 ± 11.2, 95% CI 89.5 ± 133.8 versus 51.5 ± 6.1, 95% CI 39.5 ± 63.4 months). Relapse-free survival rate was less in the group receiving low-dose AZA and shows the importance of effective dose of AZA in maintenance therapy.
Identifiants
pubmed: 33638242
doi: 10.1111/1756-185X.14075
doi:
Substances chimiques
Immunosuppressive Agents
0
Azathioprine
MRK240IY2L
Types de publication
Comparative Study
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
562-566Informations de copyright
© 2021 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
Références
Behçet H. Über rezidiverende aphtöse durch ein virüs verursachte Geschwüre am Mund, am Auge, und an den Genitalien. Dermatol Wochenschr. 1937;105:1152-1157.
Davatchi F, Chams-Davatchi C, Shams H, et al. Behçet's disease: epidemiology, clinical manifestations, and diagnosis. Expert Rev Clin Immunol. 2017;13(1):57-65.
Alibaz-Öner F, Direskeneli H. Management of vascular Behçet’s disease. Int J Rheum Dis. 2019;22(Suppl 1):105-108.
Yazici H, Ugurlu S, Seyahi E. Behçet syndrome: is it one condition? Clin Rev Allergy Immunol. 2012;43:275-280.
Hatemi G, Silman A, Bang D, et al. EULAR Expert Committee. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67(12):1656-1662.
Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behçet's syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40(4):769-774.
Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med. 1990;322:281-285.
Saadoun D, Wechsler B, Terrada C, et al. Azathioprine in severe uveitis of Behçet's disease. Arthritis Care Res (Hoboken). 2010;62(12):1733-1738.
Hatemi G, Seyahi E, Fresko İ, Talarico R, Hamuryudan V. One year in review 2019: Behçet's syndrome. Clin Exp Rheumatol. 2019;37(Suppl 121):3-17.
Merashli M, El Eid R, Uthman I. A review of current management of vasculo-Behçet's. Curr Opin Rheumatol. 2018;30(1):50-56.
Hatemi G, Merkel PA, Hamuryudan V, et al. Outcome Measures Used in Clinical Trials for Behçet Syndrome: A Systematic Review. J Rheumatol. 2014;41:599-612.